|
|
 |
|
Viewing report
|
|
|
|
Strategic Perspectives: Female Sexual Dysfunction - Are Physicians and Patients Ready For a Female Viagra?
Datamonitor, Sep 2002
Affecting an estimated 90 million women across the seven major pharmaceutical markets, sexual dysfunction is one of the most common and least talked about problem that women experience. Less than 20% of individuals who have problems with sexual functioning discuss the issue with their physician. Embarrassment, lack of awareness of services and concerns about financial cost all serve as barriers to presentation.Evaluation of the size of the FSD market, including age and subgroup breakdown, based on published epidemiological data and physician research.Detailed analysis of FSD treatment patterns within the seven leading country markets: the US, Japan, Germany, France, Italy, Spain, and the UKAssessment of unmet need and attitudes to drug therapy among the key prescribing groupsIn-depth analysis of the key drugs in mid to late stage development, including evaluation of published clinical trial dataPhysician opinion surrounding the use of drug therapy in FSD remains divided, reflecting their conceptualization of FSD as primarily psychological in origin. Nevertheless, physicians across the major markets agree that there is a need for effective short-term therapies, albeit in a relatively small proportion of the population. Despite these reservations, the approval of Viagra and Intrinsa is expected to drive a surge in treatment rates, as physicians offer therapeutic trials of these agentsAn estimated 94% of patients fail to present or withdraw from treatment following diagnosis. Fulfilling FSD’s commercial potential will hinge upon generating greater awareness among the patient and physician populationLeft unaddressed, lack of clarity around FSD’s classification will negatively impact every facet of drug developmentProvides strategies to optimize presentation, diagnosis and treatment rates, maximizing the patient potential available to therapiesIdentifies the key physician and patient variables impacting FSD treatment patternsAnalyzes the potential barriers to effective trial design and recruitmentEvaluates the unmet needs within current treatment and the potential pitfalls for companies seeking to develop FSD therapiesIdentifies key opportunities to maximize the commercial potential of pipeline therapies
Customers who bought this item also bought
Stakeholder Opinions: Female Sexual Dysfunction - Results From Datamonitors 2005 Physician Survey
Treatment Algorithms 2001: Allergic Rhinitis - Unlocking the Real Patient Potential
Female Sexual Dysfunction: Prescription Drug Pipeline Overview 2007
Treatment Algorithms 2002: Alzheimer's Disease - Aricept: the physicians choice
Treatment Algorithms 2002: Venous Thromboembolism Acute Therapy
Treatment Algorithms 2001: Schizophrenia - The Rise of Atypical Neuroleptics as the Physicians’ Favorite
Treatment Algorithms 2001: Lung Cancer
Br Malls Participacoes Sa
Br. Holdings Corporation
Treatment Algorithms 2001 Breast Cancer: Herceptin Falling into Stride
Treatment Algorithms 2002: Heart failure - managing chronic and acute patients
TPA in Stroke: Treatment Patterns and Potential
|
|
|
|
